We therefore aimed to evaluate the predictive value of baseline plasma NT-proBNP level for successful cardioversion with flecainide in patients with < 24 h symptomatic AF (i.e., acute onset with AF symptoms lasting less than 24 h). The gene discussed is NPPB; the disease is atrial fibrillation.